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Abstract
Innovative anticancer treatments continuously require tissue bioengineeringmodels to test novel
therapies. The increasing number of developments based on nanotechnology for cancer therapy or
theragnostics demand simple, reliable, fast and cost-effective cancer in vivomodels for preclinical
testing.However, despite themany tumormodels available, very few reproduce the complex
intratumoral cell-to-cell interactions as well as the accompanying systemicwhole body effects
resulting of the tumor organmetabolic, hormonal or growth factor activities, all having critical
implications in the success of cancer therapies.Here we describe a reliable tumormodel that can be
easily reproduced to generate visible solidmalignantmelanoma tumor organswithin a defined period
of 5–10 days recapitulating the tumor stroma that is essential for cancer development. Thesemodels
can be easily evaluated in vivo or by anatomo-pathological procedures. Thismethod provides a fast,
reproducible, reliable and cost-effective way to generate solid tumors for in vivo therapy, drug,
nanomaterial or imaging probe evaluation, diagnostic or theragnostic screening and validation.
1. Introduction
Pharmacological and pharmacodynamic evaluation of
new chemicals or nanomaterials in cancer requires
inexpensive, reproducible and easily available models
of study. Anticancer drug or nanomedicine effects are
currently first investigated in vitro, in 2D and 3D cell
culture systems grown from different cancer cells.
These models provide a fast, reasonably efficient,
inexpensive and reproducible ways of evaluating new
anti-proliferative or cytotoxic therapies. However,
there is ample bibliography that demonstrates how
many in vitro validated chemicals do not behave as
expected in vivo,when tested in real tumors. Themain
reason for this failure is the fact that real tumors are
not just simple disorganized masses of tumoral cells
[1]. Instead, tumors behave like real organs, interact-
ing with the body releasing growth factor into the
blood stream.
Tumors have a complex cellular organization
where cancer cells are just a small proportion of all
cells in the organ. Tumors consist of two basic compo-
nents, the proliferating neoplastic parenchymal cells
and the stroma. The parenchymal tumor cells
contribute to the growth and evolution of the tumor
and are mostly located at the proliferating borders of
solid neoplasms. The stroma includes the extracellular
matrix components, the mesenchymal supporting
cells, the cells of the vascular system and the cells of the
immune system that infiltrate the cell mass. The stro-
mal cells provide sustain and survival to cancer cells,
actively participating in tumorigenesis and vasculo-
genesis. Therefore, the interactions between the par-
enchymal cancer cells and stromal components are
critical in tumor growth and progression [1, 2].
Solid cancers are often characterized by intratu-
moral hypoxia and acidosis [3, 4]. Both play a funda-
mental role in tumor progression, resistance and are
associated with a significantly increased risk of metas-
tasis and patient mortality. Therefore, hypoxia and
acidosis are highly desirable in tumor models for they
are critical in every aspect of cancer biology and cancer
therapy screening [3, 5].
Among the different tissue bioengineering
approaches to model 3D cancer in vitro the most typi-
cal formats are (i) spheroids, (ii) cells cultured as mul-
ticellular aggregates or organoid cultures, and (iii) cells
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or synthetic engineered matrices [6–8]. These approa-
ches, applied in the study of pancreatic [9], prostate
[10], squamous cell carcinoma [11], melanoma [12],
or esophageal carcinoma [13] among many others,
reproduce intratumoral hypoxia reasonably well [14].
A simple 3D multicellular culture model is the
organotypic culture [15]. This system allows the
in vitro growth of small samples of malignant tissues
that replicate the original tumor cell types, at least dur-
ing the initial culture steps [7]. However, as these
explants grow in vitro, the cell population in the cul-
ture evolves and often macrophages and tumoral cells
are the only two cell types well represented.
Transplantation models are areal alternative strat-
egy for anti-cancer therapy screening. Cancer cell
xenotransplantation is often performed in species
such as the zebra fish or the chick embryonated eggs.
However, although these systems are inexpensive and
do not precise special bioethical requirements, they
are quite laborious, and do not allow a sufficiently
reproducible systematic study for accurate statistical
evaluation of the therapy tested.
Mammalian models are more interesting from the
therapeutic and pharmacological-point of view. Their
physiology, body temperature, pharmacodynamics,
toxicology, etc can all be reasonably extrapolated to
humans. As with the above methods, there are also
many alternatives, benefits and limitations for these
model systems. The simplest model consists of trans-
plantation of tumor tissues or cells into a host reci-
pient of identical genetic background or strain. This
type of transplant is known as allograft or syngeneic
transplant. The main advantage of this experimental
approach, typically performed in mice, is the presence
of a normal host immune system that does not reject
the tissue. A well-known example of this type of trans-
plantation models is to produce melanoma tumors in
C57BL/6J mice injecting B16F10 cells in intrave-
nously. This system is interesting to induce a systemic
tumorigenesis, most frequently triggering metastasis
in lungs [16].
Paradoxically, the main advantage of this system is
also themain disadvantage since cancer tissues and the
recipient must share a common genetic background
and thus, this model is limited to allograft transplants
from the same species, i.e. murine tissue to murine
host models, exhibiting a systematic rejection of
human cancer cells.
Xenograph transplantation in mice is also possi-
ble. The host mice however, must have an impaired
immune systems so the transplanted foreign cells or
tissues are not rejected. These xenotransplantation
techniques are typically performed in immuno-
depressed Athymic Nude [17–19] or also NOD SCID
mice [20–23]. There are many advantages in these sys-
tems. First, (i)mice are mammalian cancer model sys-
tems, (ii) there is no rejection, (iii) and there is a tumor
organ development. Moreover, these mice allow the
transplantation of small cancer tissue pieces, thus
permitting the amplification of a replica of the whole
tumoral microenvironment, including the different
cell types existing in the tumor, growingmalignant cell
masses that are highly representative of the properties,
progression and genetic variability of the particular
cancer in study. These feature also allow the develop-
ment of ‘avatar mice’ for ad personam drug testing
[24]. But there are also disadvantages in these two
models. The acquisition and housing of these mice is
very expensive, in particular that of the Athymic Nude
strain, since they are highly susceptible to opportunis-
tic viral and bacterial infections. In addition, the
immunodeficiency in these mice does not mimic the
real tumor micro-environmental situation. Also,
tumor growth in these models is slow, requiring 3–6
weeks [25].
Here we describe a new technique to develop
tumor organs inmurine neonatemice that has numer-
ous advantages, namely (i) is a mammalian system
where there is (ii) no rejection, (iii) a complete tumor
organ development, (iv) is fully reproducible, (v)
allows therapy (drugs or nanomedicines) testing, (vi) is
fast (tumors develop in 6–15 days), (vii) easy and (viii)
inexpensive. Other benefits include a complete tumor
organ development that allows therapeutic interven-




Animal work was conducted in accordance with the
Guide for the ‘Care and Use of Laboratory Animals’ of
the SpanishMinistry of Science, Research and Innova-
tion. All methods were approved by The Committee
on the Ethics of Animal Experiments of the University
of Cantabria according to current EU legislation (RD
1201/2005). Next to that, all efforts were made to
minimize the suffering of the mice. All animal
experimentation procedures were performed huma-
nely, according to EU legislation following the princi-
ple of the ‘Three Rs’, in the use of animals.
2.2. Cell culturing
B16F10 murine melanoma cells (ATCC® CRL-6475™)
were cultured in 100mm diameter culture Petri dishes
filled with 10ml of Iscove’s Modified Dulbecco’s
Medium (IMDM) containing 10% fetal bovine serum
and antibiotics (all fromLife Technologies). The cells are
grown in standard cell culture conditions, 37 °C 5%
CO2 in a humidified incubator and re-plated every 2
days to assure cell viability. Further cell line details or
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2.3. Experimental preparation
CD1 mice are used as hosts for cell transplantation.
Whole litters bearing 10–16 pups aged 2–9 (P2–P9, see
the text) were used for the experiment. Mouse pups
were transplanted with a total of 2×105 B16F10
murine malignant melanoma cells (ATCC® CRL-
6475™) in a volume of 10 μl of IMDM (Live Technol-
ogies) containing 10% serum and gentamicin subcuta-
neously (figure 1). Typically, a 70%–80% cell
confluence Petri dish containing B16F10 melanoma
cells was employed to transplant a single whole litter.
The cell suspension was transitorily resuspended in
10 ml of complete tissue culture medium for cell
counting in a Neubauer chamber. Cell numbers were
adjusted to approximately 2×105 cells per ml.
Aliquots of 1 ml were collected in 1.5 ml sterile
centrifuge tubes that were maintained at 37 °C until
the transplantation set u. is ready. Cells were finally
collected by centrifugation in a volume of in 10 μl of
sterile tissue culturemedium containing antibiotics.
2.4. Sample size and transplantation procedure
The number of pups per litter significantly conditions
the speed of the pup development and thus, the final
tumor size. This inherent in vivo artifact is reduced
taking each litter as an independent experiment. All
littermates should be injected simultaneously follow-
ing identical procedures. A total of 10 μl of melanoma
cells is sterile tissue culture medium containing
antibiotics is loaded in a 25–50 μl Hamilton syringe
for intra-scapular subcutaneous injection.
2.5. Therapy testing procedure
Animal monitoring should determine when the treat-
ment should be applied (see the text and figures). Once
tumors have developed, each litter should be divided
in two halves for the drug/therapy testing study, using
half of the litter as a control-i.e. injected with the
control excipient used for the treatment in study-, and
the other half as subject of the screening or testing
treatment-i.e. drugs, nanomaterials, probes, etc-
(figure 2). This procedure reduces to a maximum the
inherent noised of the in vivo screening system,
reducing to a maximum the unspecific statistical
variability.
2.6. Anatomo-pathology of the tumoral organs
Tumor growth evaluation is performed by anatomo-
pathology. Mice should be sacrificed preserving the
cervical region intact, for instances by anesthetic
overdose. Tumor masses, localized in the interescapu-
lar region are carefully dissected. The final tumor size
can be measured on the freshly dissociated tumors or
fixed tissue (volume measurement or weight). Micro-
scopic detailed analysis can be carried out in formalde-
hyde fixed tumors that can be routinely processed for
paraffin embedding and sectioning and hematoxylin–
eosin staining. Final tumor sizes can be statistically
evaluated using a standard software, i.e. Sigma Plot 8.0
(Systat Software, Richmond, CA).
2.7. Electronmicroscopy
Tissue samples processed for electron microscopy
were fixed with 1% glutaraldehyde in 0.12 M phos-
phate buffer, during 24 h, were washed in 0.12 M
phosphate buffer, post-fixed in 1% buffered osmium
tetroxide, dehydrated in a graded acetone series and
embedded in Araldite. Semi-thin sections (1 μm)
were stainedwith 1% toluidine blue to assess the cells.
Ultrathin sections, 70 nm thick, were obtained on an
LKB ultramicrotome, stained with lead citrate and
uranyl acetate and observed in a Jeol 1011
microscope.
3. Results
3.1. Tumor growthmonitorization in vivo
The under-developed immune system of these host
mice together the growth factor and hormonal condi-
tions in their tissues ensure a perfect tumoral environ-
ment to support solid pigmented tumors that develop
in 4–10 days (figure 3) [26]. The developing pigmented
tumor masses can be easily monitored 2–4 days post-
transplantation in live animals though the skin
(figure 3). Black cellmasses can be very easily identified
6–8 days post-transplant. At this time treatments such
Figure 1. Steps in tumor organ development. (A)Murinemelanoma cell line culture and amplification in vitro. (B) Subcutaneous
interscapular transplantation of 2×105melanoma cells per host. (C) Solid pigmentedmelanoma tumor localization and
identification (arrow).
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as intratumoral drug delivery can be easily performed.
If the study requires larger tumors, solid melanoma
masses can be allowed to grow for other 3–7 days
(figure 3(C)). Black subcutaneous masses can be easily
identified in life animals and after sacrifice for further
tumor analysis (figure 4).
Tumoral organs can be allowed to grow for differ-
ent time periods depending of the type of screening to
be performed. However, as the host develops the
immune system, the tumor growth rate diminishes,
achieving a final tumoral organ size of up to 500 mg.
As a general rule, host mice do not develop cachexia.
Therapy can be applied 5–14 days post-transplant
depending on the experimental requirements, i.e.
desired tumor size at treatment, or required final
tumor size. A simple day-by-day directmonitorization
of the tumoral mases can be performed for in real time
for therapy testing. Tumor characterization and eva-
luation by conventional techniques can also be per-
formed (i.e. ultrasonography).
Figure 2.Experimental design. Awhole liter is used for the experiment. All pups of the litter are transplanted following identical
procedures (as described in the text).Mice bearing visible tumors are blindly divided into two groups for the treatments.
Figure 3.Development of the tumor organ. (A)Postnatal day 4mice two days after transplant. Arrows point at the injection point. (B)
Visible subcutaneous interescapular transplantation pigmented tumors in postnatal day 8 pups, 5 days post-transplant. Arrows
indicate the localization of the tumor. This image demonstrates the high reproducibility of this tumor transplantation technique. (C)
Postnatal 15mouse bearing a solidmelanoma tumor (arrow).
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3.2. Anatomo-pathology of the tumoral organs
Transplantation of melanoma cells generate very
similar solid pigmented melanoma tumors in all the
pups of the litter with a maximum degree of reprodu-
cibility (figure 3). Macroscopically these tumoral
masses are generally well encapsulated, vascularized,
Figure 4.Macroscopic evaluation of the generated tumors. (A)This image shows the location andmacroscopic characteristics of
variousmelanoma tumors in 12 day oldmice littermates (5 days post-transplant). Black pigmented tumors are easily identifiable for
anatomo-pathological evaluation. The reproducibility of the technique is also patent. (B)Close up image of one of amelanoma tumor
in situ. The tumor is generally encapsulated, well vascularized and can be easily dissected for further analysis (5 days post-transplant).
Figure 5.Experimental reproducibility. (A)This histogram represents thefinalmelanoma tumor sizes in transplantedmice and the
influence of host age at transplantation. Tumorswere dissected 10 days post transplantation andweighed.Mice transplanted at
postnatal day 2 display significantly larger tumors thanmice transplanted at older ages. Notice that tumor size variability is smaller in
oldermice. (B) Final tumor sizes inmice transplanted a postnatal day 4 allowed to develop for 6, 11, 12 and 14 days. These results
indicate that 11–12 days post-transplant enhance the experimental reproducibility. (C)Representative tumor organ growth
reproducibility in postnatal day 4 transplantedmice, processed 6 days post-transplant. (D)Tumor organ reproducibility in postnatal
day 4 transplantedmice, processed 14 days post-transplant.
5
Biomed. Phys. Eng. Express 00 (2016) 000000 LGarcía-Hevia et al
and have variable sizes depending on various key
factors, namely (i) age at transplantation, and (ii) days
that the tumoral mass is allowed to grow (figure 4).
Tumoral organs can vary form 2–500 mm depending
on these factors. Figure 5 shows the variability
expected for the final tumoral masses according to
these two factors. Histological examination of these
tumors reveal cell masses constituted of well-orga-
nized and pigmented melanoma parenchymal cells
that intermingle with multiple other cell types and
extracellularmatrix components (figure 6). Neovascu-
larization of the tumor masses is also observed. These
tumors display typical standard malignant melanoma
aggressive features such as (i) a high mitotic rate, (ii)
intratumoral necrotic foci, (iii) expansive growth
edges and (iv) infiltration of surrounding tissues
-namely fat, muscle and peripheral nerves-, (v) or a
significant inflammatory response, among others
(figures 6 and 7). Summarizing, these tumor organs
are highly representative of naturally developing
tumor organs and display classical hallmarks of cancer
including sustained angiogenesis.
3.3. Versatility of themodel
This tumor model system is highly versatile allowing
the in vivo testing and validation of single treatments o
repeated dosages of different therapies, from drugs to
engineered nanomaterials, different pre-treatments
[27, 28], diagnostic probes such as quantum dots for
tumor localization or magnetic nanomaterials for
diagnosis, theragnostics therapies, etc. Moreover,
these therapies can be applied by all possible routes
including (i) intra-venous, (ii) intra-muscular, (iii)
subcutaneous, (iv) oral, (v) intra-tumoral injection or
by any other parenteral route, etc.
3.4. Reproducibility of themodel
Reproducibility of the experimental conditions is
generally themajor handicap of in vivo therapy testing.
This tumor models are highly reproducible compared
to most 3D tumoral models that often produce tumor
cell masses are not directly comparable in different
individuals, mostly due to experimental artifacts
resulting from complex technical approaches. This
experimental variability does not allow to discriminate
the effect of the therapy tested from that of the being
investigated compared to that of the placebo or
control. Figures 3–5 show the high degree of reprodu-
cibility of the system reducing to a minimum the
inherent noise of these type of transplantation
experiments.
Figure 6.Microscopic anatomo-pathological characteristics the generatedmelanoma tumors. (A)Hematoxylin–eosin section of
tumor displaying typicalmalignant tumoral features such as expansive tumor edges, and neovascularization. The transplanted cells
occasionally develop infiltrating tumoral cellmasses of pigmented epithelialmelanoma cells (arrow). (B)Detail of the pigmented cell
masses within the tumoral organ. (C)Detail of the acantholysis surrounding small blood vessels loadedwith visible erythrocytes
(arrow). (D)These tumors present a solid pseudo-papillary pattern and acantholysis (loss of intercellular connections). A significant
inflammatory response, a highmitotic rate, intratumoral necrotic foci are also observed.
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4.Discussion
The urgent need for the development of simple, cost-
effective and physiologically relevant models in cancer
clinical trials has forced to develop many different
experimental systems to reproduce tumoral condi-
tions. As a first approach, preclinical drug testing
typically performed in vitro is likely to produce mean-
ingful results. However, as the assays and questions
become more refined, tissue culture models cannot
recapitulate many aspects of human cancers including
the genesis, progression, and clinical course. Hence,
in vivo cancer models displaying different degrees of
sophisticationmust be used to test cancer therapeutics
or diagnostic probes. Among these, the murine model
is themostwidely used tool.
There aremanymurinemodels currently available
that replicate countless tumoral characteristics. At the
present time, there are murine cancer models that can
be developed ad hoc, on the basis of particular clinical
trial or studies. Among these there are (i) genetic trans-
genic germline models, (ii) gene knock-outs and
knock-ins, (iii) conditional or inducible cancer sys-
tems, (iv)models of insertional mutagenesis, (v) RNA
interference cancer models, (vi) viral-mediated muta-
genesis, (vii) treatment with chemical carcinogens,
(viii) murine chimeras, etc. However, genetic mouse
models are far too sophisticated, difficult to produce,
expensive and take months or years to developed, and
thus result inaccessible formany laboratories.
The transplantation models discussed in the intro-
duction of this manuscripts are more versatile for rou-
tine assays and, compared to genetic models, are low-
cost for general therapy testing.However, whilemost of
these systems can provide meaningful results for many
drug or therapy aspects, most of these experimental
models lack the degree of reproducibility necessary to
perform a reliable statistical analyses. This study pro-
vides a new alternative model for preclinical drug test-
ing in vivo that is reliable, cost-effective, reproducible
and only takes a few days for the experimental setup to
generate tumor organs for therapy screening in vivo.
5. Conclusion
The development of new therapies requires simple but
reliable models for screening, ideally mammalian 3D
multicellular models that can be easily monitored by
untrained scientists to allow a fast preliminary evalua-
tion of new compounds. Most mammalian in vivo
systems require high tech skills that are often inex-
istent in most routine laboratories. Here we describe a
mouse cell transplantation model for the study of
cancer therapies that can be monitored by naked eye,
can be treated with any putative therapy by any route,
is fully reproducible and thus, is a highly convenient
for most routine preclinical therapy testing assays,
making in vivo therapy evaluation simple and efficient.
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